A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…

A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…
ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine…
Luis A. Marcos, MD, MPH, Saika Sharmeen, DO, Jaime Gonzalez, MD, Qingping Yao, MD, PhD, Bettina Fries, MD, & Jack Fuhrer, MD |
In March 2020, an elderly married couple living on Long Island, N.Y., presented to our emergency department with symptoms suspicious for COVID-19 infection. The wife, a-76-year-old woman, presented with complaints of subjective fevers, minimal dry cough and headaches of one-week duration. She denied having any chills, rhinorrhea, diarrhea, abdominal pain or shortness of breath. Two…
Marinka Twilt, MD, MSCE, PhD, & Peter B. Stoustrup DDS, PhD |
Juvenile idiopathic arthritis (JIA) can affect all joints, including the temporomandibular joints (TMJs). For a long time, the TMJ was a “forgotten” joint in pediatric rheumatology, although Sir Frederick Still did comment on a small mandible in his first case series on juvenile arthritis in 1897. In recent years, more attention has been given to…
Marilynn Larkin |
NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…
ATLANTA—Macrophage activation syndrome (MAS), a subset of hemophagocytic lymphohistiocytosis (HLH) disease, can be a fatal result of rheumatic disease. But there’s good news: New therapeutic options for refractory MAS targeting individual cytokines are emerging. At the 2019 ACR/ARP Annual Meeting, possible therapeutic options were presented during a pediatric-focused clinical and translational research track, Therapeutic Approaches…
ATLANTA—With more than 3,000 abstracts from 103 countries presented at the 2019 ACR/ARP Annual Meeting in November, it was impossible for attendees to view them all. However, two ACR/ARP veterans—Arthur Kavanaugh, MD, from the University of California, San Diego, and John Cush, MD, from UT Southwestern Medical School, Dallas—chose to tackle the nearly impossible task and…
Randy Q. Cron, MD, PhD, & W. Winn Chatham, MD |
The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.
ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…
ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…